LFST vs PACS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
LFST · LifeStance Health$13.77 ▲ 2.53%
PACS · PACS Group$49.60 ▼ 1.20%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- LFST +114.2%
- PACS +296.8%
Head to head
| Metric | LFST | PACS |
|---|---|---|
| Price | $13.77 | $49.60 |
| Change today | ▲ 2.53% | ▼ 1.20% |
| Market cap | $5.24B | $7.87B |
| Return, 3 months | +15.7% | +2.4% |
| Return, year to date | +95.6% | +29.2% |
| Return, 1 year | +118.9% | +302.6% |
| P/E (TTM) | 76.5 | 28.2 |
| P/B | 3.5 | 6.5 |
| P/E percentile vs own 5y | 91st | 58th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +26.1% | +9.1% |
| Net profit growth (YoY) | +722.8% | +49.8% |
| Gross margin | 33.6% | 16.6% |
| Operating margin | 4.9% | 7.4% |
| Net margin | 3.2% | 4.8% |
| Return on equity | 3.4% | 28.1% |
| Analyst target vs. price | +6.2% | +16.9% |
| Analyst buy share | 89% | 100% |
| RSI (14) | 62 | 60 |
| 30-day volatility | 37.8% | 44.4% |
| Max drawdown, 1 year | -17.1% | -27.9% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- PACS is the largest of the group by market value.
- PACS has returned the most over the past year.
- PACS carries the lowest trailing P/E.
- LFST is growing revenue fastest.
- PACS keeps the most profit per dollar of sales.
- LFST has been the calmest stock over the last 30 days.